Rivaroxaban Market Is Expected to Witness a CAGR of 1.5% over the Forecast Period (2018 – 2026)

Seattle, WA — (SBWIRE) — 11/07/2019 — Rivaroxaban, marketed as Xarelto, is a non-vitamin K antagonist oral anticoagulants (NOAC) that is used in the prevention or treatment of serious illnesses and potentially life-threatening conditions associated with blood coagulation. Rivaroxaban was discovered by Bayer and is being jointly developed with Janssen Research & Development, LLC.

Read the full press release at http://www.sbwire.com/press-releases/rivaroxaban-market-is-expected-to-witness-a-cagr-of-15-over-the-forecast-period-2018-2026-1264487.htm